← All trials
NCT06473701
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2024
- Primary completion
- Apr 30, 2026
- Completion date
- Jul 31, 2026
- First posted
- Jun 25, 2024
- Last posted
- Jun 25, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Region SyddanmarkLead sponsor
- University of Southern DenmarkCollaborator
- Region of Southern DenmarkCollaborator
- University of Southern DenmarkCollaborator
- Aarhus UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.